India Slashes Medical Device License Waits by 25 Days to Boost $13B Market

For hospital administrators and healthcare providers, the speed at which new medical devices become available directly influences patient outcomes. India's draft amendments to slash licensing timelines for devices like pulse oximeters and cardiac stents by up to 25 days mean that critical equipment can reach operating rooms and ICUs faster, potentially at lower costs. As the country works to reduce its 70% import dependence, this regulatory overhaul could reshape procurement strategies and supply chain resilience across the health system.

The Union Health Ministry of India has proposed a series of amendments to the Medical Devices Rules, 2017, aimed at dramatically reducing the statutory timeline for manufacturing licenses. Announced on June 28, 2026, the proposal seeks to cut wait times for Class B low- to moderate-risk devices from 140 days to 115 days, a reduction of 25 days, and for high-risk Class C and Class D devices—which include cardiac stents, hip implants, and other critical life-saving technologies—from 105 days to 90 days. The move is a direct response to long-standing industry complaints about bureaucratic delays that have throttled the growth of domestic manufacturing in a sector where India imports roughly 70% of its devices. With the Indian medical device market estimated at $13 billion by the India Brand Equity Foundation (IBEF), the reforms are designed to enhance ease of doing business, improve regulatory efficiency, and accelerate patient access to quality medical products.

“

Moreover, the amendments could synergize with the recently announced National Medical Device Policy, 2023, which envisions a six-fold increase in the sector's size to $50 billion by 2030.

The proposed amendments introduce defined timelines for each stage of the licensing process—initial scrutiny, audits by notified bodies, compliance verification, and final license issuance. This granular approach is intended to inject transparency and predictability, moving away from an opaque system where delays were common. While Class A (lowest risk) devices already faced minimal regulation, the real impact will be felt in the higher-risk categories that constitute the bulk of clinical usage. For manufacturers, a 25-day acceleration for a blood pressure monitor or a pulse oximeter may not seem transformative, but the reduced uncertainty allows better production planning and faster inventory turnover. For high-risk implants, the 15-day cut can be crucial, especially when launching new products or scaling up to meet sudden demand surges, as witnessed during the COVID-19 pandemic.

India's medical device sector has been a policy priority since the launch of the Production-Linked Incentive (PLI) scheme in 2020-21, which allocated approximately ₹3,420 crore to boost domestic manufacturing of key devices like CT scanners, MRIs, and ventilators. However, industry stakeholders have consistently flagged regulatory hurdles as a major bottleneck. The Central Drugs Standard Control Organisation (CDSCO), which oversees device regulation, has faced capacity constraints and a shortage of notified bodies to conduct audits. The new timelines will only work if sufficient resources are deployed; otherwise, mandated deadlines could become unenforceable, breeding further frustration. The ministry has acknowledged this indirectly by linking the amendments to the broader agenda of 'ease of doing business,' but concrete steps to augment regulatory infrastructure remain unstated.

From a global perspective, the move aligns with India's ambition to become an alternative manufacturing hub to China, particularly after supply chain disruptions during the pandemic exposed vulnerabilities. Countries like the United States and the European Union have encouraged diversification, and India's large skilled workforce and lower production costs make it attractive. Streamlined licensing would position India not only as a supplier for its vast domestic market but also as an exporter to Southeast Asia, Africa, and Latin America. International medical device giants—Siemens Healthineers, GE Healthcare, and Medtronic—already have manufacturing footprints in India; quicker approvals could encourage them to expand production lines or introduce more advanced products locally.

For patients, faster licensing translates into more rapid availability of next-generation devices at potentially lower costs. Currently, imported devices carry a premium due to duties and logistics. Domestic production, once scaled, can offer competitive pricing, as seen in the generic pharmaceutical sector. However, the quality assurance aspect cannot be overstated. The ministry's statement emphasizes that the reductions will not compromise quality, safety, or performance requirements. Notified bodies will still conduct audits, and compliance verification remains mandatory. The real test will be whether the system can maintain rigor under pressure to meet shortened deadlines.